ArticleJCEM case reports2025
Glycemic Derangements With Capivasertib-From Hyperglycemia to Diabetic Ketoacidosis: A Report of 3 Cases.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Managing capivasertib-induced hyperglycemia: a report of 3 cases.JCEM case reports · 2026Article
- Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients.Journal of diabetes investigation · 2026Article
- Continuous glucose monitoring reveals bimodal glycemic patterns during and outside Capivasertib administration.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capiversatib is a pan-Ak strain transforming inhibitor used in combination with fulvestrant for the treatment of hormone receptor-positive advanced breast cancer and has a known adverse effect of hyperglycemia. We present 3 cases of severe hyperglycemia, 2 of which presented as diabetic ketoacidosis, in patients being treated with capivasertib. These cases demonstrate the severity of hyperglycemia that can result from capivasertib use, as well as highlight treatment regimens and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.